文献园地
更多
TheranosticsDevelopment of a nanoparticle-based immunotherapy targeting CD137 for nasopharyngeal carcinoma treatment
International ImmunopharmacologySiglec-E deletion alters AT macrophages phenotypes, induces an inflammatory response, and adipogenesis during diet-induced obesity
Journal of Orthopaedic ResearchDepth-Wise Changes in Tibial and Femoral Human Knee Joint Cartilage at Different Severities of Osteoarthritis
品牌库
更多tranScrip Ltd
Established in October 2008, TranScrip Partners was specifically created to meet the needs of pharmaceutical companies forced to reduce head counts and consequent access to in-house drug development expertise. TranScrip is structured to fill this gap in the market and can provide pharmaceutical and life science companies with the expertise they require in a wide range of sub-disciplines and therapeutic areas, on both a short and long term basis, drawn from its extensive pool of Senior Partners and Partners.
Abbott B.V.
We are a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. Our products span the continuum of care, from nutritional products and laboratory diagnostics through medical devices and pharmaceutical therapies. Our comprehensive line of products encircles life itself - addressing important health needs from infancy to the golden years.
Formatech, Inc. Company dissolved
At Formatech, we help make new drugs happen… at the speed of science! Formatech, founded in 1993, provides contract services that deliver unique solutions to our clients' product development and manufacturing challenges. Our service offerings include: preformulation and formulation development of all common dosage forms, lyophilization development, cell culture/fermentation process development, purification/downstream process development and aseptic fill and finish of liquid and lyophilized dosage units. We have had excellent results developing biotherapeutic products. Our accomplishments include developing many Ab formulations at concentrations in excess of 200 mg/mL and an orally bioavailable peptide formulation. Our aseptic manufacturing facility produces liquid and lyophilized dosage units for clinical supplies or small-scale commercial products. Manufacturing support services include compounding/formulation, diafiltration/concentration (UF/DF), release testing, and ICH conforming stability programs. Our team is accomplished at completing new projects successfully even when confronted with very aggressive timelines. Our regulatory history includes FDA inspections and three inspections by the MHRA (letters and certificate of GMP compliance received).
GUS Schweiz AG
We optimize your business processes GUS ERP GmbH, GUS Nordic ApS and GUS Schweiz AG provide GUS-OS Suite, a web-based ERP business solution that includes all industry functionalities and fulfills regulatory requirements. The companies are members of the GSG GENII Software Group (www.gsg-genii.com), which offers leading, industry-specific software solutions and services, explicitly for medium-sized companies and public administrations. With its industry knowledge and personal customer relationships, the group of companies is a trustworthy partner and expert advisor to its customers. It accompanies its customers through digitization and ensures that they are equipped for the future in a volatile environment. GENII, headquartered in Munich, Germany, has generated sales of approximately 340 million euros with around 2,400 employees. GENII is backed by Bregal Unternehmerkapital and Elvaston.
GUS ERP GmbH
As a long-standing partner of the process industry, the GUS Group combines business competence with industry expertise and offers with GUS-OS ERP one of the most comprehensive software offerings for companies in the pharmaceutical, biotechnology, cosmetics, food and beverage, chemical and logistics industries. The GUS Group provides comprehensive consulting services, carries out projects and sets up IT infrastructures. Our own development team ensures continuous software innovations and the alignment of the solution with the norms and standards in our target industries. Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here .
Dr. August Wolff GmbH & Co. KG
Dr. August Wolff GmbH & Co. KG Arzneimittel is a family owned research oriented company still located in Bielefeld, Germany. Dr. August Wolff GmbH & Co. KG is selling medicinal products, medical devices and cosmetic products like Linola and Vagisan in several European countries. Since its inception in 1905 Dr. August Wolff has maintained strong focus in collaborations with universities to foster research and development in their search for novel products.
生知快讯
最新资讯
更多
创新药每日资讯 · 2026-10-24
创新药日报第 53 期来了。本期头条是百利天恒全球首款双抗 ADC 再下一城；国际端默沙东/Moderna 的 mRNA 癌症疫苗拿下首个 III 期阳性、吉利德 12.75 亿美元现金收购瀚辰星泰；政策端医保国谈进入签约阶段。3 分钟看完 8 条。本期索引1️⃣ 百利天恒宜泽康 HR+/HER2- 乳腺癌 NDA 获 CDE 受理（10/23）2️⃣ 默沙东/Modern
创新药每日资讯 · 2026-10-23
今日创新药圈 3 件大事：FcRn 重症肌无力新药获批、全球首个司库奇尤单抗类似药落地、ESMO 2026 马德里开幕（主席专场中国研究占 5 席）。3 分钟看完① 和铂/石药巴托利单抗获批上市，1 类新药攻坚全身型重症肌无力② 百奥泰司库奇尤单抗获批，全球首个该品种生物类似药（银屑病/强直/银屑病关节炎）③ 恒瑞瑞维鲁胺获批
创新药每日资讯 · 2026-10-22
创新药圈今天有点热闹：基因编辑治地中海贫血交出「28/28 脱离输血」的成绩单，AI 巨头第一次买下「管研发进度」的公司，国产 Bcl-2 和 TSLP 单抗双双往前迈了一步。3 分钟看完今天的 8 条动态① 邦耀生物 RM001：II 期 28 例受试者全部脱离输血超 1 年，最长随访 5 年，全球首个 HBG1/2 启动子靶点基因编辑疗法② 亚盛医